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Extensive research suggests a role for the innate immune system in the pathogenesis of depression, but most of the
studies are conducted in adult populations, in high-income countries and mainly focus on the study of inﬂammatory proteins alone, which provides only a limited understanding of the immune pathways involved in the
development of depression. The IDEA-FLAME study aims to identify immune phenotypes underlying increased
risk of developing depression in adolescence in a middle-income country. To this end, we will perform deepimmunophenotyping of peripheral blood mononuclear cells and RNA genome-wide gene expression analyses in
a longitudinal cohort of Brazilian adolescents stratiﬁed for depression risk. The project will involve the 3-year
follow-up of an already recruited cohort of 150 Brazilian adolescents selected for risk/presence of depression
on the basis of a composite risk score we developed using sociodemographic characteristics (50 adolescents with
low-risk and 50 with high-risk of developing depression, and 50 adolescents with a current major depressive
disorder). We will 1) test whether the risk group classiﬁcation at baseline is associated with differences in immune
cell frequency, phenotype and functional status, 2) test whether baseline immune markers (cytokines and immune
cell markers) are associated with severity of depression at 3-year follow-up, and 3) identify changes in gene
expression of immune pathways over the 3-year follow-up in adolescents with increased risk and presence of
depression. Because of the exploratory nature of the study, the ﬁndings would need to be replicated in a separate
and larger sample. Ultimately, this research will contribute to elucidating key immune therapeutic targets and
inform the development of interventions to prevent onset of depression among adolescents.

1. Introduction
Depression is a leading cause of disability in adolescents worldwide
and is a major risk factor for suicide, the third most frequent cause of

death in adolescents globally (Thapar et al., 2012; Ferrari et al., 2013).
For adolescents suffering with depression the beneﬁts of currently
available treatments are modest at best (Cipriani et al., 2016) and large
randomised controlled trials have failed to demonstrate the efﬁcacy of
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(Kieling et al., 2019), we generated a composite risk score for the
development of depression in adolescence using sociodemographic variables (Botter-Maio Rocha et al., 2020; Brathwaite et al., 2020a). In order
to identify speciﬁc immune mechanisms associated with increased risk or
presence of depression, we will take advantage of the unique cohort (the
IDEA - Risk Stratiﬁed Cohort (IDEA-RiSCo)) of Brazilian adolescents that
has been stratiﬁed for risk and presence of depression by using this risk
score (Kieling et al., 2021). One of the innovative aspects of this cohort is
that it does not assume that adolescents without depression constitute a
homogenous group and therefore uses a risk score to stratify for risk of
future depression (low vs. high). Most of the currently available mental
health samples typically compare cases and non-cases where the latter
are deﬁned by lack of a current psychiatric disorder. However, non-cases
may have a number of risk factors that make them likely to develop a
disorder in the future, leading to a high amount of noise and heterogeneity in these typical designs. This can be rectiﬁed by risk stratiﬁcation of
non-cases (into low and high risk), such as has been done in IDEA-RiSCo.
Of note, the IDEA risk score includes sociodemographic variables (such as
childhood maltreatment, social isolation, drug use etc.) that have previously been associated with increased levels of inﬂammatory markers
(Baumeister et al., 2016; Zilioli and Jiang, 2021; Carbia et al., 2021). It is
therefore possible to hypothesise that the high risk, as indicated by
sociodemographic variables/IDEA risk score, would contribute to the
onset of depression partially through the modiﬁcation of the immunophenotype, as also suggested in our recently published systematic review
(Zajkowska et al., 2021).
The IDEA-FLAME study will focus on this depression risk-stratiﬁed
cohort of adolescents recruited in Brazil. Ninety percent of the world's
adolescents live in low- and middle-income countries (LMICs), yet the
majority of research on inﬂammation and depression has been conducted
in HICs (D'Acunto et al., 2019). This highlights a signiﬁcant gap in our
knowledge of immune mechanisms that could help explain how
depression develops in adolescents in LMICs, where the psychosocial
context often differs from HICs. Our research protocol focusing on the
Brazilian IDEA-RiSCo cohort will allow us to ﬁll this gap in existing
knowledge (Kieling et al., 2019). Psychosocial context can interact with
the immune system to inﬂuence the development of depression (Baumeister et al., 2016; Zajkowska et al., 2021); e.g. frequency of circulating
monocytes is increased following early experience of social adversities
(Mondelli and Vernon, 2019) and increased low-grade systemic inﬂammation predicts subsequent development of depression only in adolescents with experience of childhood adversities (Miller and Cole, 2012).
This highlights the need to identify cross-culturally and
cross-contextually immune processes that would increase our understanding of the biological mechanisms by which social experiences
impact depression risk.
The purpose of this manuscript is to present the protocol of the IDEAFLAME study, including details on the scientiﬁc methodology, laboratory
and statistical analyses to enhance transparency of research, reduce
publication bias and prevent selective publication and selective reporting
of research outcomes, as well as to support reproducibility of results for
future research studies.

universal strategies for the prevention of depressive disorder (Stallard
et al., 2012). Widespread classroom-based prevention programmes
directed at adolescents, regardless of their risk status, have shown more
modest effects than programmes designed to target individuals at higher
risk of developing depression (Stallard et al., 2012). A barrier to developing effective preventative interventions for adolescent depression is
that we lack a sufﬁcient understanding of how depression develops
during adolescence and how to identify adolescents who are at highest
risk for depression to enable targeted prevention.
Extensive research, mainly conducted in adult populations from highincome countries (HICs), suggests a role for inﬂammation and the innate
immune system in the pathogenesis of depression (Miller and Raison,
2016). Adult patients with major depression show increased levels of
inﬂammatory cytokines including interleukin (IL)-6 and tumor necrosis
factor (TNF) in peripheral blood and cerebrospinal ﬂuid (Baumeister
et al., 2014; Enache et al., 2019). However, studies in adults cannot
inform us about the inﬂammatory mechanisms involved in the early
stages of the disorder and more speciﬁcally during adolescence when
most patients experience their ﬁrst episode of depression (Avenevoli
et al., 2015). Despite adolescence being frequently the time of ﬁrst
episode of depression, there is an evident paucity of adolescent mechanistic studies; this can be attributed to multiple factors, including ethical
considerations for potential invasive investigations (e.g. blood samples
etc.) and difﬁculties in acquiring consent. These barriers unfortunately
contribute to make this area of research less popular and more stigmatized, leading to less funding available for these studies and to widening
the gap between adolescent and adult research. So far, only a few studies
have investigated immune markers in adolescents with depression,
mainly focusing on levels of inﬂammatory proteins and suggesting a
possible increase in TNF (D'Acunto et al., 2019). However, the study of
inﬂammatory proteins alone provides only a limited understanding of the
immune pathways involved in the development of depression. Therefore,
more research is needed on cellular immune markers and gene expression of immune pathways.
The ﬁeld of immunopsychiatry is rapidly evolving and holds important potential for developing easy-to-access, mechanistic biomarkers for
prevention and treatment of mental health disorders (Caldwell et al.,
2020). We have recently shown the potential utility of cellular immune
markers to distinguish inﬂamed and uninﬂamed subgroups of depression
in adult individuals (Lynall et al., 2019). Deep cellular immunophenotyping is an important approach to identifying fundamental causal
mechanisms, that could not be implied by limiting our focus on downstream markers, such as cytokines and C-reactive protein. Although
activation of innate immune response has largely dominated the landscape of research in depression, some studies have also demonstrated an
impairment in acquired immune response involving the potential neuroprotective effects mediated by Treg cells (Miller and Raison, 2016).
Our recent ﬁndings show an increased frequency of CD4þ T cells in adults
with depression (Lynall et al., 2019). Therefore, the investigation of
phenotypic and functional features of both myeloid and lymphoid immune cells, that we would address with the IDEA-FLAME study, hold the
potential to better identify and reﬁne the immune system's role in the
pathogenesis of depression in adolescents. On the other hand, transcriptomic analyses, including our own work, has shown abnormal
expression of gene networks important for the regulation and implementation of innate immune response in adults with depression (Cattaneo et al., 2018; Wittenberg et al., 2020). In line with recent widely
endorsed views encouraging maximising the potential of immunopsychiatry (Caldwell et al., 2020), the IDEA-FLAME research protocol includes application of high-throughput cutting-edge laboratory
techniques such as multiparameter ﬂow-cytometry and RNA-Seq to a
well-characterised cohort of adolescents stratiﬁed by risk of depression.
A stratiﬁed medicine approach is needed to transform mental health
research and to support more tailored interventions and better targeting
of treatments (Schumann et al., 2014). As part of our previous work
within the Identifying Depression Early in Adolescence (IDEA) project

2. Aims and hypotheses
Our IDEA-FLAME study aims to address some of the above challenges
by investigating immune mechanisms underlying increased risk of
developing depression in adolescence, by performing deepimmunophenotyping and RNAseq analyses in a longitudinal cohort of
adolescents stratiﬁed for depression risk. The follow-up of the IDEARiSCo cohort has been planned for 3 years after the baseline assessments were conducted because 3 years was the prediction interval for
which the IDEA risk score was originally developed (i.e. the score
calculated at age 15 predicted increased risk of depression at age 18)
(Botter-Maio Rocha et al., 2020). More speciﬁcally this study aims to: 1)
Test whether increased risk or presence of adolescent depression is
2
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3.1. Description of IDEA - Risk Stratiﬁed Cohort (IDEA-RiSCo)

associated with differences in immune cell frequency, phenotype and
functional status (cross-sectional analyses on baseline samples). 2) Test
whether baseline immune markers (cytokines and immune cell markers)
are associated with depressive symptoms at follow-up (longitudinal analyses between baseline and 3-year follow-up). 3) Identify changes in
immune pathways (or to identify novel pathways) over a 3-year period in
adolescents with increased risk and presence of depression vs those with
low-risk of depression (longitudinal analyses between baseline and
3-year follow-up).
We hypothesise that: 1) Adolescents with depression and those with
high-risk of future depression will present increases in percentage and
activity of classical and non-classical monocytes compared with low-risk
adolescents. We also hypothesise that depressed adolescents will present
with increases in percentage of CD4þ T cell when compared with adolescents with low- and high-risk of depression. For the ﬁrst aim we also
plan to take a hypothesis-free approach as we will additionally investigate other cell types and their frequency and phenotype (e.g. dendritic
cells activation markers, cytokines production etc). 2) Higher levels of IL6 and TNF at baseline will be associated with more severe psychopathology at 3-year follow-up. 3) Adolescents with depression and those
with high-risk of future depression will present similar changes between
baseline and 3-year follow-up in the expression of pathways and networks regulating the innate immune response that will not be apparent in
adolescents with low-risk for future depression.

In order to stratify risk of developing major depression among adolescents, we have previously developed a composite score using data
from the Pelotas 1993 Birth Cohort (Goncalves et al., 2014). Using only
sociodemographic variables obtained from the adolescent at age 15, we
developed the IDEA risk-score, which has good discriminative performance (c-statistic of 0.78) to identify individuals at high-risk for developing major depression at age 18 (Botter-Maio Rocha et al., 2020). In the
Pelotas 1993 Birth Cohort, adolescents scoring above the 90th percentile
at age 15 years had a 38% probability of depression three years later;
among those below the 20th percentile none had a depressive episode at
age 18 years. The composite risk score has subsequently been shown to
perform beyond chance in other countries (including the UK) (Botter-Maio Rocha et al., 2020; Brathwaite et al., 2020a; Brathwaite et al.,
2020b).
As part of the IDEA project, we have established a new cohort (IDEARiSCo) of 150 Brazilian adolescents that has been stratiﬁed for risk and
presence of depression by using the IDEA risk-score (see Fig. 1). A total of
7720 adolescents aged 14–16 years of age were initially screened in
public state schools in Porto Alegre, Brazil. One hundred and ﬁfty adolescents were selected for inclusion in the study based on their risk scores
derived from the screening information and subsequent clinical assessment to check for current and lifetime history of depressive disorders
(including dysthymia) using the Brazilian Portuguese translation of the
Schedule for Affective Disorders and Schizophrenia for School-Age
Children-Present and Lifetime Version (K-SADS-PL) (Caye et al., 2017).
At baseline, the 150 adolescents were aged 14–16 years, 50% were female, and 44% of African descent. Participants were classiﬁed into one of
three groups at baseline: a group of 50 low-risk participants with no
current or past depression who were at or below the 20th percentile on
the risk score; a group of 50 high-risk participants with no current or past
depression at baseline but at or above the 90th percentile on the risk
score; and a group of 50 participants with a current, untreated, episode of
major depression and at or above the 90th percentile on the risk score
(Kieling et al., 2021). To allow for two-by-two comparisons between

3. Methods
IDEA-FLAME is a nested explorative research project within the larger
Identifying Depression Early in Adolescence - Risk Stratiﬁed Cohort
(IDEA-RiSCo) study, which aims to understand the neurobiological
mechanisms of adolescent depression risk by studying a longitudinal
cohort of 150 adolescents stratiﬁed at baseline for risk/presence of
depression (50 adolescents with low-risk, 50 adolescents with high-risk
of future depression, 50 adolescents with current, untreated, depression) recruited from schools in Porto Alegre in Brazil (Kieling et al.,
2021).

Fig. 1. Overview of the IDEA-RiSCo study: recruitment process, the baseline data already available, data collected and analysed as part of other two nested studies
(BRAIN-IDEA and IDEA-TECH) and analyses to be conducted as part of IDEA-FLAME.
3
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cell suspension was transferred to a Nunc cryovial and stored in a Coolcell™ freezing container at 80  C overnight. Finally, the samples were
transferred into liquid nitrogen in the local laboratory in Brazil, before
being shipped in liquid nitrogen to King's College London, where the ﬂow
cytometry analyses will take place.

groups, adolescents with current depression were also required to score
at or above the 90th percentile of the risk score.
3.2. Clinical assessments and data collection supported by the larger IDEA
project

3.3.2. Multi-parameter ﬂow cytometry analysis
To reveal immunopathological processes implicated in development
of depression and establish phenotypic and functional differences between the three groups we will perform deep-immunophenotyping of
PBMCs collected from participants at baseline. Using multi-parameter
ﬂow cytometry, we will investigate phenotypic and functional features
of myeloid (monocytes, dendritic cells [DC]) and lymphoid (B cells, T
cells, NK) immune cells, obtaining i) cell frequency of major populations
and relative subsets (e.g., Tregs, Th1, Th2, Th17), ii) expression level of
activation, maturation, adhesion and inhibitory markers, and iii) production of cytokines. We will run 3 high dimension 14-colours ﬂow
cytometry panels including: 1) a myeloid cell phenotypic panel
(including surface and intracellular markers) to study activation (e.g.,
HLA-DR), maturation (CD80, CD83), adhesion (CD54) and inhibitory
(PD-L1) markers; 2) a lymphoid phenotypic panel including a surface
marker to study frequency and phenotype of B, T and NK cells by
assessing activation (CD69); and 3) a lymphoid functional panel
including phenotypic markers (as above) and cytokines (following
stimulation for 5 hours by L phorbol-12-myristate-13-acetate and ionomycin in the presence of monensin and brefeldin) for the detection of
intracellular cytokines (e.g. IFN-γ, TNF, IL-4,IL-17). Samples will be run
on a BD FACS Fortessa x20 instrument at King's College London (KCL),
where the PBMCs are currently stored, using Standardized Application
Setup which allows combining of data acquired in different experiments,
thus minimising batch-effects.

The baseline assessment included a clinical diagnostic interview (KSADS-PL) (Caye et al., 2017) with both adolescent and caregiver by a
board-certiﬁed child psychiatrist, and validated self-report measures of
depression symptoms, including the Brazilian Portuguese adaptation of
the Mood and Feelings Questionnaire (MFQ) (Rosa et al., 2018). At the
baseline assessment, we conducted structural and functional brain MRI
scans and collected blood and saliva samples for measuring inﬂammatory
proteins and performing RNAseq analyses, and isolated peripheral blood
mononuclear cells (PBMCs) for future immune-related analyses (IDEA-FLAME study). Further information about the clinical measurements
included in the baseline assessment and full description of the
IDEA-RiSCo cohort have been published in a previous paper (Kieling
et al., 2021).
Two online follow-ups with clinical questionnaires have also been
conducted at 1- and 2-years following baseline assessment maintaining
an exceptionally high retention rate (1-year: 95.33%, still ongoing 2years: 96.09%). The 3-year face-to-face follow-up has been approved
by the National Ethics Committee in Brazil and includes clinical assessment, smartphone-based passive and active sensing (nested study IDEATECH), brain MRI scans (nested study BRAIN-IDEA) and collection of
blood samples (see Fig. 1). Local ethical approval for secondary data
analyses is currently being sought in the UK and Italy where the laboratory analyses will take place and will be obtained before starting the
laboratory work. The assessment of clinical symptoms at follow-up includes the administration of multiple scales (i.e., depressive symptoms
measured with the Children's Depression Rating Scale-Revised (Poznanski et al., 1985), anxiety measured with the Spence Children's Anxiety
Scale (Spence, 1998; DeSousa et al., 2014), irritability measured with the
Affective Reactivity Index (Stringaris et al., 2012), and suicidality
measured with the dimensional scales of the Columbia-Suicide Severity
Rating Scale (Posner et al., 2011)). To assess rates of conversion to
depression diagnosis, we will use the Brazilian Portuguese version of the
K-SADS-PL (Caye et al., 2017). We will also assess whether participants
sought any type of treatment for depression since baseline assessment.

3.3.3. Cytokines analyses
At the 3-year follow-up serum samples will be collected to measure a
range of pro- and anti-inﬂammatory cytokines (e.g., IFN-γ, IL-1β, IL-2, IL4, IL-6, IL-10, IL-17A and TNF) using high sensitivity multiplex arrays
(i.e., V-plex pro-inﬂammatory panel 1 and cytokine panel 1 human kits)
with a Meso Scale Discovery instrument. We will use the same technique
and instrument used for measuring these cytokines in the baseline samples and already reported in detail in other publications (Enache et al.,
2021; Nettis et al., 2021).

3.3. Analyses to be conducted as part of the IDEA-FLAME study
3.3.4. RNA sequencing
At 3-year follow-up we will collect blood samples using PAXgene
tubes for RNAseq analyses, and will follow the same protocol used for the
baseline samples which resulted in good quality RNA samples. More
speciﬁcally, RNA from all baseline samples have been isolated from
PAXGene tubes following the manufacturer's instruction and were
immediately stored at 80  C for the subsequent analysis. The handling
as well as the storage of the samples has been performed according to
standard practice guidelines to avoid any deterioration. The quality of
each sample has been checked by using Agilent Bioanalyzer 2100 and the
RNA Integrity Number (RIN) has been checked for each sample. The RIN
number is a software algorithm that indicates the RNA intactness by
evaluation of the ribosomal ratio (18S and 28S) and it is based on a
numbering system from 1 to 10, with 1 indicating a degraded proﬁle and
10 the most intact (Mueller and Schr€
oder, 2004); for genome-wide gene
expression analysis, the RIN value is considered to be good when it falls
within the range of 7–10. At baseline, 146 out of 150 samples (93% of the
entire cohort of samples) had a RIN value above 7.5, indicating intact and
very good quality RNA; moreover, among these, 97 samples show RIN
>9.
RNA sequencing analyses will be run at the University of Milan, Italy,
where the ﬁrst baseline samples have been analysed in order to use the
same instrument. Brieﬂy, RNA-Sequencing libraries will be prepared
using the TrueSeq Stranded Total RNA Sample Preparation kit (Illumina),

For the nested IDEA-FLAME study we will conduct immune phenotyping of the IDEA-RiSCo cohort by 1) expanding the study of immune
biomarkers at baseline, analysing immune cell markers in PBMCs previously collected and cryopreserved, and 2) repeating some of the measurement of inﬂammatory proteins and RNAseq analyses from blood
samples collected at 3-year follow-up. Ethical approval has already been
received in Brazil for collection of samples and analyses for IDEA-FLAME.
Local ethical approval for secondary data analyses is currently being
sought in the UK and Italy where the laboratory analyses will take place
and will be obtained before starting the laboratory work.
3.3.1. PBMCs separation and storage
At baseline assessment, blood was collected in two 4ml EDTA tubes
by peripheral venipuncture, then carefully layered over conical Falcon
tubes pre-ﬁlled with 1077-Histopaque for density gradient centrifugation
according to the manufacturer's instructions. Tubes were centrifuged at
400g for 30 minutes at room temperature with the brake off. Following
aspiration of the top plasma layer, the buffy coat interphase layer containing the PBMCs was collected and washed three times in PBS at 250g
for 10 minutes at room temperature with brake on. Cell viability was
evaluated by Trypan blue exclusion staining and found to exceed 90%.
Cell pellet was then resuspended in 1 ml of cryoprotectant solution (90%
fetal bovine serum and 10% DMSO) added drop wise over the cells. The
4
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(approximately 40 participants per group). In our previous work (Lynall
et al., 2019), we found a correlation between a Principal Component
score (mostly weighted on myeloid cells and CD4þ T cells) and severity of
depressive symptoms with a ρ ¼ 0.26. For aim 2, considering a sample of
120 subjects, using G*Power we computed a power of 83% to detect a
similar effect size (using a two-tailed p value of 0.05) for a correlation
between immune markers and severity of depressive symptoms. For aim
3, focusing on RNAseq analyses and by using the ssizeRNA package we
determined that a sample size of 40 per group has a power of 92% for
detecting signiﬁcantly different expressed genes, with FC of 2, FDR ¼
0.05 and considering 15000 as the number of detected genes and 0.1 as
the dispersion parameter for each gene (Bi and Liu, 2016).

using the Ribo-Zero Gold kit (Illumina) for depletion of ribosomal RNA,
followed by ﬁrst and second strand cDNA synthesis and fragmentation of
dsDNA. Then, fragmented DNA will be used for A-tailing, adaptor ligation and 12 cycles of PCR ampliﬁcation. Libraries will be quantiﬁed using
high sensitivity chip on a Labchip (PerkinElmer), quantitative PCR
(KAPA Library Quantiﬁcation, Kapa Biosystems), and PicoGreen (Life
Technologies). Three libraries will be run per lane of an Illumina HiSeq
2000 (100bp paired-end), which should yield 60 million reads/library.
3.4. Statistical analyses
For aim 1, we will use generalized linear models to examine whether
risk group classiﬁcation (high-risk, low-risk, depressed) is associated
with differences in cellular immune markers at baseline. To reduce the
likelihood of overﬁtting to our sample and increase the possibility of
generalising our ﬁndings to other datasets, we will conduct stratiﬁed 5fold cross-validation in all of our statistical analyses (with ~10 participants from each of three risk groups randomly assigned to each of the 5
subsamples for testing the models). For aim 2, we will test associations
between baseline cytokine levels and clinical presentation at 3-year
follow-up, while controlling for baseline depression symptoms, by
using partial correlation. We will also control for whether participants
sought any treatment in the intervening period, and examine whether
this moderates the association between risk group status at baseline and
follow-up depression symptoms. For both aim 1 and 2, we will test the
contribution of potential confounders (smoking, obesity, medical
comorbidities) by including each variable in turn in the model (general
linear model for aim 1 and partial correlation for aim 2) and see whether
any identiﬁed association would remain statistically signiﬁcant after
introducing each confounder. To explore the potential role of other factors inﬂuencing the immune phenotype, we will also conduct explorative
correlation analyses to test associations of factors such as relationship/
attachment with parents with the immune markers identiﬁed to be speciﬁcally relevant for the onset of depression. For the bioinformatic analyses for RNAseq data: as for the baseline, we will use FastQC for
checking the quality of the data; FASTX-Toolkit and Trimmomatic for
adapter and over-represented sequences trimming; Bowtie2 for alignment; TopHat for transcript counting; and DESeq2 for differential
expression analysis. Following high-throughput sequencing, 100bp
paired-end reads will be aligned to the hg19 human genome using
TopHat v2.1.0 (http://tophat.cbcb.umd.edu/) with a mate insert distance of 75 bp (-r) and library type fr-unstranded. Reads passing a
mapping quality of at least 50 will be used for gene and transcript
quantiﬁcation and DESeq2 will be used for differential expression analysis. Data will also be imported in Ingenuity Pathway Analyses Software
(IPA) and Gene Mania Software in order to identify pathways which are
differentially modulated.

4. Discussion
The IDEA-FLAME study is the ﬁrst project aiming to perform deep
immune phenotyping and whole-genome transcriptomic analysis of adolescents with or at risk of depression. It has the advantage of leveraging
on a unique risk-stratiﬁed cohort of adolescents and addressing the issues
of comparing adolescents with depression with a potentially widely
heterogenous sample of controls. Understanding immune cells and
pathways involved in the development and increased risk of adolescent
depression will help to better identify adolescents at high risk of developing depression at an early stage and potential key therapeutic targets to
inform the development of interventions to prevent onset of depression
among adolescents worldwide. These steps are extremely important to
improve our understanding of adolescent depression and contribute to
the development of effective early interventions that would potentially
reduce the burden of depression in adolescents in the future.
The results from this study will support future work that in the longterm could lead to: 1) prediction of clinical outcomes/trajectory, 2)
identiﬁcation of immune targets for developing speciﬁc antiinﬂammatory interventions suitable for adolescent depression, and 3)
identiﬁcation of distinct subtypes of adolescents who would potentially
beneﬁt from anti-inﬂammatory treatment strategies. The development of
personalised early intervention strategies guided by immune mechanistic
biomarkers will improve identiﬁcation of adolescents at risk at an early
stage, support targeted prevention efforts, and better treatment for
adolescent depression. Ultimately, a better understanding of the immune
mechanisms underlying adolescent depression and the identiﬁcation and
characterization of adolescents at higher risk of developing depression
could potentially contribute to future prevention and treatment strategies
leading to a reduction in the incidence of depression among adolescents
and adults across the globe.
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the 1993 Pelotas study, we assume a retention rate of around 80% at
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